Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Buys 4,259 Shares

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis bought 4,259 shares of the business’s stock in a transaction that occurred on Tuesday, September 24th. The shares were bought at an average cost of $4.70 per share, for a total transaction of $20,017.30. Following the transaction, the director now owns 41,767 shares of the company’s stock, valued at $196,304.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Rezolute Stock Performance

Shares of NASDAQ RZLT traded down $0.10 during midday trading on Tuesday, hitting $4.69. 366,095 shares of the stock traded hands, compared to its average volume of 439,218. The firm has a 50-day moving average of $4.62 and a two-hundred day moving average of $3.76. The firm has a market capitalization of $188.23 million, a P/E ratio of -4.20 and a beta of 1.18. Rezolute, Inc. has a one year low of $0.72 and a one year high of $6.10.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). Equities analysts forecast that Rezolute, Inc. will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC grew its position in Rezolute by 366.0% in the second quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after acquiring an additional 42,597 shares in the last quarter. Affinity Asset Advisors LLC grew its position in Rezolute by 15.6% in the second quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock worth $7,955,000 after acquiring an additional 250,000 shares in the last quarter. Marshall Wace LLP purchased a new position in Rezolute in the second quarter worth about $4,503,000. XTX Topco Ltd boosted its position in shares of Rezolute by 205.8% during the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock valued at $145,000 after buying an additional 22,660 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Rezolute during the second quarter valued at approximately $255,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on RZLT. Guggenheim began coverage on Rezolute in a report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. Maxim Group boosted their target price on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. BTIG Research boosted their target price on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Craig Hallum initiated coverage on Rezolute in a research note on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $7.00 target price on shares of Rezolute in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $11.57.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.